Scarica l'app Stockscreener
0.00
100.00%
-46.99
Dopo l'orario di chiusura:
46.98
46.98
+
Precedente Chiudi:
$46.99
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$3.52B
Reddito:
-
Utile/perdita netta:
$-275.16M
Rapporto P/E:
0.00
EPS:
-3.89
Flusso di cassa netto:
$-221.15M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Nome
Springworks Therapeutics Inc
Settore
Industria
Telefono
203-883-9490
Indirizzo
100 WASHINGTON BOULEVARD, STAMFORD, CT
Confronta SWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
0.00 | 3.52B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-20 | Iniziato | Evercore ISI | Outperform |
| 2024-02-05 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-03-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-08 | Iniziato | Cowen | Outperform |
| 2019-10-08 | Iniziato | Goldman | Buy |
| 2019-10-08 | Iniziato | JP Morgan | Overweight |
| 2019-10-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Springworks Therapeutics Inc Borsa (SWTX) Ultime notizie
Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence - MSN
How volatile is SpringWorks Therapeutics Inc. stock compared to the marketEarnings Report Opportunities To Watch Now - jammulinksnews.com
What institutional investors are buying SpringWorks Therapeutics Inc. stockBeginner Investor Tips With Low Risk - jammulinksnews.com
Should I hold or sell SpringWorks Therapeutics Inc. stock in 2025Value Investing Data Feed For Beginners - jammulinksnews.com
What catalysts could drive SpringWorks Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - jammulinksnews.com
Published on: 2025-07-30 08:30:59 - metal.it
Published on: 2025-07-29 02:19:36 - beatles.ru
Sentiment Tools Show Shift in Trader Mood on SpringWorks Therapeutics Inc.Conservative Entry for High Return Setup Backed - metal.it
What makes SpringWorks Therapeutics Inc. stock price move sharplyEarly Breakout Entry Point Notifications Sent - metal.it
Is SpringWorks Therapeutics Inc. a growth stock or a value stockUnlock exclusive stock market forecasts - jammulinksnews.com
What are SpringWorks Therapeutics Inc. company’s key revenue driversAchieve breakthrough investment performance - jammulinksnews.com
Is SpringWorks Therapeutics Inc. stock overvalued or undervaluedFree Market Volatility Navigation Tips - jammulinksnews.com
Why SpringWorks Therapeutics Inc. stock attracts strong analyst attentionEarly Breakout Tracker - metal.it
What drives SpringWorks Therapeutics Inc. stock priceDynamic portfolio growth - Autocar Professional
Is SpringWorks Therapeutics Inc. a good long term investmentFree Market Volatility Navigation Tips - PrintWeekIndia
What analysts say about SpringWorks Therapeutics Inc. stockFree Investment Community - PrintWeekIndia
SpringWorks Therapeutics Inc. Stock Analysis and ForecastConsistent wealth multiplication - PrintWeekIndia
Neurofibromatosis Type 2 Pipeline 2025: MOA and ROA Insights, - openPR.com
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - MSN
European Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 Patients - Nasdaq
European Commission Grants Conditional Approval of EZMEKLY® - GlobeNewswire
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - Yahoo Finance
California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know - Nasdaq
Principal Financial Group Inc. Decreases Stock Position in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
CIBRA Capital Ltd Purchases New Holdings in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics - Hartford Business Journal
Merck completes $3.4bn acquisition of SpringWorks Therapeutics - World Pharmaceutical Frontiers
Merck concludes SpringWorks acquisition for $3.4bn - Yahoo Finance
SpringWorks Therapeutics, Inc.(NasdaqGS: SWTX) dropped from S&P TMI Index - MarketScreener
SpringWorks Therapeutics Completes Merger and Delisting - TipRanks
SpringWorks Therapeutics: Unlocking Value Through Merck's EU Regulatory Milestones - AInvest
Springworks Therapeutics Inc Azioni (SWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):